Europe’s drug pricing split: UK leans pro‑industry while Germany eyes cuts and higher fees

European nations are feeling mounting pressure to rein in drug prices, a trend that is reshaping the market for both manufacturers and patients across the continent.

In the United Kingdom, lobbying from pharmaceutical firms and signals from the United States have prompted the government to adopt policies that are more favorable to the industry, alongside pledges to increase overall spending on medicines.

Germany, by contrast, is confronting a growing health‑budget shortfall and is proposing measures that would reduce public drug spending and raise the fees that companies must pay to operate.

These divergent approaches highlight how European policymakers are balancing cost containment with access, while also testing the extent of U.S. influence on regional health‑care strategies.